We prepare our consolidated financial statements in United States dollars and in accordance with generally accepted accounting principles as applied in the United States, (“U.S. GAAP”). In this Annual Report on Form 10-K, references to “$” and “dollars” are to United States dollars.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Lead asset; consists of proenzymes trypsinogen and chymotrypsinogen (activated forms trypsin and chymotrypsin). Phase 1b first-in-human study planned in advanced cancer patients with solid tumors; LC-MS PK assay development engaged Mar 2026 (FyoniBio GmbH). No study start date stated.
POP1
Discovery · Active
Partnerships Universities of Jaen (UJA) and Granada (UGR), Spain: multi-year joint research collaboration (Mar 2026)
Status note Joint research and drug discovery program designed to produce a backup clinical compound to PRP; also evaluating a senescence-modulating (anti-aging) compound to support fibrosis and cancer patent claims.
Per-asset detail extracted from the 10-Q filed 2026-05-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.